Zacks Investment Research lowered shares of Glaukos (NYSE:GKOS) from a hold rating to a sell rating in a research report report published on Tuesday.
According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “
Other equities research analysts also recently issued reports about the stock. ValuEngine downgraded shares of Glaukos from a hold rating to a sell rating in a research report on Monday, February 5th. Cantor Fitzgerald set a $48.00 price target on shares of Glaukos and gave the stock a buy rating in a report on Wednesday, January 10th. BMO Capital Markets restated a buy rating on shares of Glaukos in a report on Monday, December 11th. Finally, Stephens restated an overweight rating and set a $40.00 price target (down from $47.00) on shares of Glaukos in a report on Monday, November 13th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. Glaukos presently has an average rating of Hold and a consensus target price of $44.86.
Shares of Glaukos (GKOS) opened at $31.07 on Tuesday. The company has a market cap of $1,081.20, a PE ratio of 260.67, a PEG ratio of 45.33 and a beta of 1.21. Glaukos has a 52-week low of $23.08 and a 52-week high of $52.49.
In other news, CFO Joseph E. Gilliam purchased 2,100 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were acquired at an average cost of $23.84 per share, for a total transaction of $50,064.00. Following the completion of the acquisition, the chief financial officer now owns 102,100 shares in the company, valued at $2,434,064. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 16.40% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its stake in Glaukos by 7.2% in the third quarter. Janus Henderson Group PLC now owns 3,344,361 shares of the medical instruments supplier’s stock valued at $110,364,000 after acquiring an additional 225,105 shares during the last quarter. Bamco Inc. NY boosted its stake in Glaukos by 104.6% in the third quarter. Bamco Inc. NY now owns 2,194,059 shares of the medical instruments supplier’s stock valued at $72,404,000 after acquiring an additional 1,121,813 shares during the last quarter. William Blair Investment Management LLC boosted its stake in Glaukos by 7.5% in the fourth quarter. William Blair Investment Management LLC now owns 1,979,960 shares of the medical instruments supplier’s stock valued at $50,786,000 after acquiring an additional 137,969 shares during the last quarter. BlackRock Inc. boosted its stake in Glaukos by 6.5% in the fourth quarter. BlackRock Inc. now owns 1,957,114 shares of the medical instruments supplier’s stock valued at $50,200,000 after acquiring an additional 119,811 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Glaukos by 3.4% in the second quarter. Vanguard Group Inc. now owns 1,668,345 shares of the medical instruments supplier’s stock valued at $69,187,000 after acquiring an additional 55,507 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: This news story was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/02/17/glaukos-gkos-rating-lowered-to-sell-at-zacks-investment-research.html.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.